
Diagnostics Pipeline: Cizzle Bio Introduces Test for Earlier Lung Cancer Detection
The CIZ1B biomarker blood-based assay has 95% sensitivity for detecting earliest stage of the cancer

The CIZ1B biomarker blood-based assay has 95% sensitivity for detecting earliest stage of the cancer

The startup is trying to close the care gap between female and male patients

The momentum for targeted therapies has downstream implications for clinical laboratories

New liquid biopsy assay will be used in conjunction with 500 cancer patients currently enrolled in clinical trials

Proper dosing helps prevent potential side effects such as developing diabetes and kidney damage